tradingkey.logo

Co-Diagnostics Inc

CODX
0.235USD
-0.006-2.41%
Close 12/26, 16:00ETQuotes delayed by 15 min
11.31MMarket Cap
LossP/E TTM

Co-Diagnostics Inc

0.235
-0.006-2.41%
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison

TradingKey Stock Score of Co-Diagnostics Inc

Currency: USD Updated: 2025-12-26

Key Insights

Co-Diagnostics Inc's fundamentals are relatively very healthy, and its growth potential is good.Its valuation is considered fairly valued, ranking 128/207 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 1.25.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Co-Diagnostics Inc's Score

Industry at a Glance

Industry Ranking
128 / 207
Overall Ranking
327 / 4563
Industry
Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Analyst Rating

Based on 2 analysts
Buy
Current Rating
1.250
Target Price
+260.33%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Co-Diagnostics Inc Highlights

StrengthsRisks
Co-Diagnostics, Inc. is a molecular diagnostics company, which develops, manufactures and markets diagnostics technologies. The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious disease. Its diagnostics systems enable dependable, low-cost, molecular testing for organisms and genetic diseases by automating or simplifying historically complex procedures in both the development and administration of tests. It is developing a portable diagnostic device and test system designed for point-of-care and at-home use. The system consists of its PCR instrument that it refers to as the Co-Dx PCR Pro instrument, its proprietary diagnostic test cup system and a mobile application to be installed on the user’s mobile device.
Growing
The company is in a growing phase, with the latest annual income totaling USD 3.92M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 3.92M.
Overvalued
The company’s latest PE is -0.24, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 11.14M shares, decreasing 2.69% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 867.52K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 10.46.

Financial Health

Currency: USD Updated: 2025-12-26

The current financial score of Co-Diagnostics Inc is 5.96, ranking 182/207 in the Healthcare Equipment & Supplies industry. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 145.38K, representing a year-over-year decrease of 77.32%, while its net profit experienced a year-over-year decrease of 39.29%.

Score

Industry at a Glance

Previous score
5.96
Change
0

Financials

9.15

Key Metrics

Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.

Quality of Earnings

7.57

Operational Efficiency

2.83

Growth Potential

3.20

Shareholder Returns

7.07

Co-Diagnostics Inc's Company Valuation

Currency: USD Updated: 2025-12-26

The current valuation score of Co-Diagnostics Inc is 6.74, ranking 156/207 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -0.24, which is -17.53% below the recent high of -0.20 and -2868.59% above the recent low of -7.16.

Score

Industry at a Glance

Previous score
6.74
Change
0

Valuation Dimensions

P/E
P/B
P/S
P/CF
Industry Ranking 128/207
Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2025-12-26

The current earnings forecast score of Co-Diagnostics Inc is 7.00, ranking 151/207 in the Healthcare Equipment & Supplies industry. The average price target for Co-Diagnostics Inc is 1.25, with a high of 1.50 and a low of 1.00.

Score

Industry at a Glance

Previous score
7.00
Change
0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 2 analysts
Buy
Current Rating
1.250
Target Price
+260.33%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

90
Total
4
Median
7
Average
Company name
Ratings
Analysts
Co-Diagnostics Inc
CODX
2
Boston Scientific Corp
BSX
36
Edwards Lifesciences Corp
EW
34
Veeva Systems Inc
VEEV
34
Intuitive Surgical Inc
ISRG
34
Thermo Fisher Scientific Inc
TMO
27
1
2
3
...
18

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-12-26

The current price momentum score of Co-Diagnostics Inc is 6.27, ranking 153/207 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 0.35 and the support level at 0.17, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
6.24
Change
0.03

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(2)
Neutral(2)
Buy(0)
Indicators
Value
Direction
MACD(12,26,9)
-0.014
Sell
RSI(14)
36.269
Neutral
STOCH(KDJ)(9,3,3)
11.482
Oversold
ATR(14)
0.032
Low Volatility
CCI(14)
-94.445
Neutral
Williams %R
90.771
Oversold
TRIX(12,20)
-1.500
Sell
StochRSI(14)
0.000
Oversold
Moving Average
Sell(6)
Neutral(0)
Buy(0)
Indicators
Value
Direction
MA5
0.248
Sell
MA10
0.264
Sell
MA20
0.313
Sell
MA50
0.369
Sell
MA100
0.357
Sell
MA200
0.337
Sell

Institutional Confidence

Currency: USD Updated: 2025-12-26

The current institutional shareholding score of Co-Diagnostics Inc is 3.00, ranking 135/207 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 13.43%, representing a quarter-over-quarter increase of 4.41%. The largest institutional shareholder is The Vanguard, holding a total of 1.71M shares, representing 2.80% of shares outstanding, with 47.10% decrease in holdings.

Score

Industry at a Glance

Previous score
3.00
Change
0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name
Shares Held
Chg %
Orca Capital GmbH
2.19M
--
The Vanguard Group, Inc.
Star Investors
1.73M
-2.53%
Private Advisory Group LLC
1.18M
--
Renaissance Technologies LLC
Star Investors
561.02K
+1.94%
Egan (Dwight H.)
748.18K
+17.54%
Abbott (Richard David)
631.47K
+2.07%
Brown (Brian Lee)
599.30K
+16.76%
BlackRock Institutional Trust Company, N.A.
427.44K
-13.95%
Serbin (Richard S)
262.50K
+22.57%
1
2

Risk Assessment

Currency: USD Updated: 2025-12-26

The current risk assessment score of Co-Diagnostics Inc is 1.04, ranking 200/207 in the Healthcare Equipment & Supplies industry. The company's beta value is 1.20. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.

Score

Industry at a Glance

Previous score
1.04
Change
0
Beta vs S&P 500 index
1.20
VaR
+7.65%
240-Day Maximum Drawdown
+81.35%
240-Day Volatility
+170.41%

Return

Best Daily Return
60 days
+259.28%
120 days
+259.28%
5 years
+259.28%
Worst Daily Return
60 days
-54.76%
120 days
-54.76%
5 years
-54.76%
Sharpe Ratio
60 days
+0.98
120 days
+0.98
5 years
-0.09

Risk Assessment

Maximum Drawdown
240 days
+81.35%
3 years
+92.50%
5 years
+98.41%
Return-to-Drawdown Ratio
240 days
-0.85
3 years
-0.33
5 years
-0.20
Skewness
240 days
+11.10
3 years
+15.26
5 years
+17.19

Volatility

Realised Volatility
240 days
+170.41%
5 years
+107.69%
Standardised True Range
240 days
+22.18%
5 years
+92.55%
Downside Risk-Adjusted Return
120 days
+313.22%
240 days
+313.22%
Maximum Daily Upside Volatility
60 days
+699.17%
Maximum Daily Downside Volatility
60 days
+199.94%

Liquidity

Average Turnover Rate
60 days
+7.42%
120 days
+4.28%
5 years
--
Turnover Deviation
20 days
+1046.50%
60 days
+422.95%
120 days
+201.32%

Peer Comparison

Healthcare Equipment & Supplies
Co-Diagnostics Inc
Co-Diagnostics Inc
CODX
5.56 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Edwards Lifesciences Corp
Edwards Lifesciences Corp
EW
8.72 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Artivion Inc
Artivion Inc
AORT
8.50 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Lantheus Holdings Inc
Lantheus Holdings Inc
LNTH
8.48 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Tactile Systems Technology Inc
Tactile Systems Technology Inc
TCMD
8.47 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
AxoGen Inc
AxoGen Inc
AXGN
8.40 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more

FAQs

How does TradingKey generate the Stock Score of Co-Diagnostics Inc?

The TradingKey Stock Score provides a comprehensive assessment of Co-Diagnostics Inc based on 34 indicators derived from over 100 underlying data points.
These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Co-Diagnostics Inc’s performance and outlook.

How do we generate the financial health score of Co-Diagnostics Inc?

To generate the financial health score of Co-Diagnostics Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns.
By integrating these comprehensive data, the financial health score not only reflects Co-Diagnostics Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Co-Diagnostics Inc.

How do we generate the company valuation score of Co-Diagnostics Inc?

To generate the company valuation score of Co-Diagnostics Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Co-Diagnostics Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value.
By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Co-Diagnostics Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Co-Diagnostics Inc.

How do we generate the earnings forecast score of Co-Diagnostics Inc?

To calculate the earnings forecast score of Co-Diagnostics Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:
Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.
Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.
By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.
Comparing these indicators against peers provides context for the stock’s performance and helps anchor more realistic expectations.
These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Co-Diagnostics Inc’s future.

How do we generate the price momentum score of Co-Diagnostics Inc?

When generating the price momentum score for Co-Diagnostics Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.
Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.
This comprehensive approach can reflect market sentiment and enable rational forecasts of Co-Diagnostics Inc’s prices. A higher score indicates a more stable short-term price trend for Co-Diagnostics Inc.

How do we generate the institutional confidence score of Co-Diagnostics Inc?

To generate the institutional confidence score of Co-Diagnostics Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Co-Diagnostics Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Co-Diagnostics Inc.

How do we generate the risk management score of Co-Diagnostics Inc?

To assess the risk management score of Co-Diagnostics Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.
The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.
These indicators together provide a multi-dimensional understanding of Co-Diagnostics Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Co-Diagnostics Inc.
KeyAI